| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.54▼ | 1.54▲ | 1.54▼ | 1.59▼ | 1.39▲ |
| MA10 | 1.54▼ | 1.55▼ | 1.57▼ | 1.58▼ | 1.58▼ |
| MA20 | 1.54▼ | 1.57▼ | 1.58▼ | 1.40▲ | 2.08▼ |
| MA50 | 1.57▼ | 1.57▼ | 1.60▼ | 1.61▼ | 4.37▼ |
| MA100 | 1.58▼ | 1.60▼ | 1.48▲ | 2.19▼ | 4.59▼ |
| MA200 | 1.58▼ | 1.45▲ | 1.41▲ | 3.87▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.003▼ | -0.006▼ | 0.043▲ | 0.074▲ |
| RSI | 45.879▼ | 44.696▼ | 43.829▼ | 51.896▲ | 32.859▼ |
| STOCH | 45.238 | 17.525▼ | 31.506 | 73.825 | 24.321 |
| WILL %R | -71.429 | -80.000▼ | -62.500 | -30.508 | -67.879 |
| CCI | -15.746 | -26.278 | -36.977 | 35.632 | -42.825 |
|
Monday, April 28, 2025 02:00 PM
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...
|
|
Monday, April 28, 2025 01:53 PM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...
|
|
Monday, April 28, 2025 06:54 AM
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 1.60 | 1.61 | 1.5025 | 1.55 | 160,290 |
| 30/04/25 | 1.55 | 1.645 | 1.48 | 1.605 | 290,329 |
| 29/04/25 | 1.61 | 1.65 | 1.565 | 1.58 | 275,779 |
| 28/04/25 | 1.60 | 1.63 | 1.55 | 1.60 | 260,194 |
| 25/04/25 | 1.70 | 1.71 | 1.573 | 1.60 | 258,497 |
| 24/04/25 | 1.61 | 1.73 | 1.58 | 1.72 | 377,099 |
| 23/04/25 | 1.59 | 1.67 | 1.55 | 1.63 | 415,061 |
| 22/04/25 | 1.55 | 1.61 | 1.44 | 1.57 | 1,146,956 |
| 21/04/25 | 1.45 | 1.61 | 1.36 | 1.53 | 618,286 |
| 17/04/25 | 1.31 | 1.56 | 1.29 | 1.44 | 1,014,763 |
|
|
||||
|
|
||||
|
|